woman, and for a 70 Kg man, the daily intakes associated with the above EDI, expressed as µg/Kg/day and as percent RfD utilization are:

	Dietary Exposure	Percent RfD Utilized
Infant	0.65 µg/Kg/day	1.71
Child	0.47 µg/Kg/day	1.24
Woman	0.24 µg/Kg/day	0.632
Man	0.20 µg/Kg/day	0.526

Yoshitomi Fine Chemicals, Ltd. notes that at 40 CFR 180.1(l) EPA has defined that a ''negligible residue ... Ordinarily ... will add to the diet an amount which will be less than 1/2,000th of the amount that has been demonstrated to have no effect from feeding studies on the most sensitive animal species tested.'' This, for a 100-fold uncertainty factor based RfD, means an RfD utilization of 5% or less. Yoshitomi considers, therefore, that under the hypothetical worst case dietary exposure assessment RYH–86 residues are clearly negligible residues.

i. *Drinking water.* The use of RYH–86 as a slimicide for pulp and paper mills does not provide for entry of RYH–86 into drinking water sources. Spent process water from such sites is treated as waste water, typically on-site, prior to release into surface waters. In a Finnish paper mill, with a use level of 1.5 ppm in the water (as an initial load to the slurry water) no RYH–86 was detected in air or water at sites by the paper making machine (detection limits were 4.5 ng/L in water and 3×10^{-6} mg/dm^3). Water samples which were examined included samples from the waste water holding pond and discharge from the on-site waste water treatment plant.

2. *Non-dietary exposure.* RYH–86 is an industrial-use slimicide whose only other registered use (i.e., aside from slimicide use in pulp and paper mills) is as a slime control agent in re-circulating cooling water. All of the uses of RYH–86 involve only occupational exposures. There are no registrations and no intended uses in residential scenarios. There are, therefore, no Food Quality Protection Act covered non-dietary exposures to RYH–86.

D. Cumulative Effects

There is no reliable information to indicate that RYH–86 has a common mechanism of toxicity with any other chemical compound.

E. Safety Determination

1. *U.S. population.* Since the use of RYH–86 as a slimicide in pulp and paper mills is, under hypothetical worst case conditions, anticipated to lead to only negligible adult dietary exposures (i.e., not greater than 0.63% of the RfD for adults with ''negligible'' defined at 40 CFR 180.1(l) as ''ordinarily'' not greater than 5% of the RfD) Yoshitomi Fine Chemicals, Ltd. concludes that there is a reasonable certainty that no harm to the general adult population will result from dietary exposure to RYH–86 residues which could occur in food contact paper and paperboard produced in pulp and paper mills utilizing RYH–86 for slime control in accordance with its FIFRA labeling.

2. *Infants and children.* Since the use of RYH–86 as a slimicide in pulp and paper mills is, under hypothetical worst case conditions, anticipated to lead to only negligible dietary exposures (i.e., not greater than 1.71% of the RfD for infants and not greater than 1.24% of the RfD for children with ''negligible'' defined at 40 CFR 180.1(l) as ''ordinarily'' not greater than 5% of the RfD) Yoshitomi Fine Chemicals, Ltd. concludes that there is a reasonable certainty that no harm to infants and children will result from dietary exposure to RYH–86 residues which could occur in food contact paper and paperboard produced in pulp and paper mills utilizing RYH–86 for slime control in accordance with its FIFRA labeling.

3. *Sensitive individuals.* The RfD for RYH–86 is based on gastro-intestinal irritation as the effect which occurs at lowest dose in animal gavage studies. Since the effect of irritation is a physico-chemical effect, the existence of metabolic differences among persons is not reasonably expected to be a factor producing individuals with special sensitivity to RYH–86. Also, since: (a) physico-chemical effects like irritancy usually do not at all occur well below a threshold concentration of irritant; and, (b) the RfD is based on gavage studies in which RYH–86 is directly delivered to the gastric compartment whereas daily dietary consumption of the RfD amount leads to a lower peak GI tract level than would occur after gavage administration of the RfD amount, it can be expected that even for persons with pre-existing conditions such as ulcers, colitis, and similar pathologies that dietary exposures to RYH–86 at levels up to the proposed RfD will not exacerbate such conditions. Therefore, Yoshitomi Fine Chemicals, Ltd. concludes that there is a reasonable certainty that no harm to persons with pre-existing GI-tract problems will result from dietary exposure to RYH–86 residues which could occur in food contact paper and paperboard produced in pulp and paper mills utilizing RYH–86 for slime control in accordance with its FIFRA labeling.

F. International Tolerances

There are no Codex maximum residue levels (MRLs) established for residues of RYH–86 resulting from the use of RYH–86.

[FR Doc. 97–25338 Filed 9–23–97; 8:45 am]

BILLING CODE 6560–50–F

FEDERAL COMMUNICATIONS COMMISSION

[Report No. 2225]

Petitions for Reconsideration and Clarification of Action in Rulemaking Proceedings

September 19, 1997.

Petitions for reconsideration and clarification have been filed in the Commission's rulemaking proceedings listed in this Public Notice and published pursuant to 47 CFR Section 1.429(e). The full text of these documents are available for viewing and copying in Room 239, 1919 M Street, N.W., Washington, D.C. or may be purchased from the Commission's copy contractor, ITS, Inc. (202) 857–3800. Oppositions to these petitions must be filed October 9, 1997. See Section 1.4(b)(1) of the Commission's rule (47 CFR 1.4(b)(1)). Replies to an opposition must be filed within 10 days after the time for filing oppositions has expired.

Subject: Amendment of Part 90 of the Commission's Rules to Facilitate Future Development of SMR Systems in the 800 MHz Frequency Band (PR Docket No. 93–144, RMs–8117,8030,8029).

Implementation of Sections 3(n) and 322 of the Communications Act Regulatory Treatment of Mobile Services (GN Docket No. 93–252).

Implementation of Section 309(j) of the Communications Act—Competitive Bidding (PP Docket No. 93–253).

Number of Petitions Filed: 6.

Subject: Amendment of Part 90 of the Commission's Rules to Facilitate Future Development of SMR Systems in the 800 MHz Frequency Band (PR Docket No. 93–144, RMs–8117,8030,8029).

Implementation of Sections 3(n) and 322 of the Communications Act Regulatory Treatment of Mobile Services (GN Docket No. 93–252).

Implementation of Section 309(j) of the Communications Act—Competitive Bidding (PP Docket No. 93–253).

Number of Petitions Filed: 3.

Subject: Amendment of parts 2 and 15 of the Commission's Rules to Deregulate the Equipment Authorization Requirements for Digital Devices (ET Docket No. 95–19).

Number of Petitions Filed: 2.

Subject: Amendment of the Commission's Rules to Relocate the Digital Electronic Message Service from the 18 GHz band to the 24 GHz band for Fixed Service (ET Docket No. 97–99).

Number of Petitions Filed: 2.

Subject: Applicant for Authorizations and Licenses of Certain Stations in Various Services (WT Docket No. 97–115).

Number of Petitions Filed: 5.

Federal Communications Commission.

Shirley Suggs,

Chief, Publications Branch.

[FR Doc. 97–25271 Filed 9–23–97; 8:45 am]

BILLING CODE 6712–01–M

FEDERAL RESERVE SYSTEM

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Board of Governors of the Federal Reserve System.

TIME AND DATE: 12:00 noon, Monday, September 29, 1997.

PLACE: Marriner S. Eccles Federal Reserve Board Building, C Street entrance between 20th and 21st Streets, N.W., Washington, D.C. 20551.

STATUS: Closed.

MATTERS TO BE CONSIDERED:

1. Personnel actions (appointments, promotions, assignments, reassignments, and salary actions) involving individual Federal Reserve System employees.

2. Any items carried forward from a previously announced meeting.

CONTACT PERSON FOR MORE INFORMATION: Mr. Joseph R. Coyne, Assistant to the Board; (202) 452–3204. You may call (202) 452–3207, beginning at approximately 5 p.m. two business days before this meeting, for a recorded announcement of bank and bank holding company applications scheduled for the meeting.

Dated: September 19, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–25407 Filed 9–19–97; 5:06 pm]

BILLING CODE 6210–01–P

FEDERAL TRADE COMMISSION

Sunshine Act Meeting

AGENCY HOLDING THE MEETING: Federal Trade Commission.

TIME AND DATE: 12:00 p.m., Friday, November 7, 1997.

PLACE: Federal Trade Commission Building, Room 532, 6th Street and Pennsylvania Avenue, N.W., Washington, D.C. 20580.

STATUS: Parts of this meeting will be open to the public. The rest of the meeting will be closed to the public.

MATTERS TO BE CONSIDERED: Portions Open to Public: (1) Oral Argument in Brake Guard Products, Inc., Docket 9277

Portions Closed to the Public: (2) Executive Session to follow Oral Argument in Brake Guard Products, Inc., Docket 9277.

CONTACT PERSON FOR MORE INFORMATION: Victoria Streitfeld, Office of Public Affairs: (202) 326–2180. Recorded Message: (202) 326–2711.

Donald S. Clark,

Secretary.

[FR Doc. 97–25521 Filed 9–22–97; 3:40 pm]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Agency Information Collection Activities: Submission for OMB Review; Comment Request

The Department of Health and Human Services, Office of the Secretary publishes a list of information collections it has submitted to the Office of Management and Budget (OMB) for clearance in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35) and 5 CFR 1320.5. The following are those information collections recently submitted to OMB.

1. Study of the Implementation of the Office of Minority Health's Bilingual/Bicultural Service Demonstration Program—NEW—The Office of Minority Health proposes to survey sites participating in its Bilingual/Bicultural demonstration grant program to obtain general information on how the program is being implemented. *Type of Respondents:* demonstration sites; *Number of Respondents:* 47; *Burden Estimate per Response to Verification Survey:* 4 hours; *Total Burden for Verification Survey:* 188 hours; *Burden Estimate per Response to Telephone Interview:* 1 hour; *Total Burden for Telephone Interview:* 47 hours. *Total Study Burden:* 235 hours.

OMB Desk Officer: Allison Eydt.

Copies of the information collection packages listed above can be obtained by calling the OS Reports Clearance Officer on (202) 690–6207. Written comments and recommendations for the proposed information collection should be sent directly to the OMB desk officer designated above at the following address: Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, 725 17th Street N.W., Washington, D.C. 20503.

Comments may also be sent to Cynthia Agens Bauer, OS Reports Clearance Officer, Room 503H, Humphrey Building, 200 Independence Avenue S.W., Washington DC, 20201. Written comments should be received within 30 days of this notice.

Dated: September 12, 1997.

Dennis P. Williams,

Deputy Assistant Secretary, Budget.

[FR Doc. 97–25263 Filed 9–23–97; 8:45 am]

BILLING CODE 4150–04–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Ophthalmic Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA regulatory issues.

Date and Time: The meeting will be held on October 20, 1997, 9 a.m. to 5 p.m., and October 21, 1997, 8:30 a.m. to 5 p.m.

Location: Holiday Inn, Walker and Whetstone Rooms, Two Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Sara M. Thornton, Center for Devices and Radiological Health (HFZ–460), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301–594–2053, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12396, or from the Internet: http://